Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis
Authors:
- 14 March 2005
- journal article
- case report
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 30 (2) , 189-192
Abstract
We report on a patient who developed acute rhabdomyolysis after taking cerivastatin. A 74‐year‐old hypercholestrerolaemic woman taking cerivastatin (0·15 mg/day) for 22 days complained of general muscle weakness and muscle pain. Her serum creatinine phosphokinase level was 19 190 IU/L. Serum myoglobin was over 3000 ng/mL. Serum concentration of cerivastatin at 6 h after taking the last dose (0·15 mg) was 8062·5 ng/L, which was almost 5·7 times higher than that of normal persons. The serum concentration of cerivastatin showed that the half‐life of cerivastatin in this patient was 22·4 h, compared with 2·4 h for normal controls. Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M‐1, and by 2C8 to M‐23. The ratio of M‐23 to M‐1 in her serum was much lower than that of control persons (0·64 vs. 2·08). She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction.Keywords
This publication has 14 references indexed in Scilit:
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- Cerivastatin Induces Rhabdomyolysis and Acute Renal FailureNephron, 2002
- Rhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One HospitalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Effects of HMG-CoA Reductase Inhibitors on Skeletal MuscleDrug Safety, 2002
- Prognosis of Hypercholesterolemic Patients Taking Pravastatin for Five Years: The Chiba Lipid Intervention Program (CLIP) StudyJournal of Atherosclerosis and Thrombosis, 2002
- Rhabdomyolysis and HMG-CoA Reductase InhibitorsAnnals of Pharmacotherapy, 2001
- Metabolic causes of recurrent rhabdomyolysisActa Neurologica Scandinavica, 1998
- Changes in population cholesterol levels and coronary heart disease deaths in seven countriesEuropean Heart Journal, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995